Skip to main content
Log in

Preliminary results of the use of intraperitoneal carbon-adsorbed mitomycin C in intra-abdominal malignancy

  • Clinical Oncology
  • Published:
British Journal of Cancer Submit manuscript

Abstract

Eleven patients suffering from intra-abdominal malignancy were treated with various doses of intraperitoneal mitomycin C adsorbed onto activated carbon particles. Seven of the patients underwent resection of their primary gastric tumour and all developed potentially life-threatening severe complications that proved to be fatal in four patients. The pattern of complications seen in these patients was unusual in patients undergoing gastrectomy and must be presumed to be secondary to the intraperitoneal mitomycin C. Intraperitoneal mitomycin C at a dose of 25 mg and 50 mg in the presence of an anastomosis or other suture line does not appear to be safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ubhi, S., McCulloch, P. & Veitch, P. Preliminary results of the use of intraperitoneal carbon-adsorbed mitomycin C in intra-abdominal malignancy. Br J Cancer 76, 1667–1669 (1997). https://doi.org/10.1038/bjc.1997.615

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1997.615

  • Springer Nature Limited

Navigation